Berenberg downgrades GSK to 'hold' ahead of product rollouts
Analysts at Berenberg downgraded drugmaker from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.
Berenberg said GSK has delivered 12% absolute share price performance year-to-date, the highest in the sector, but despite this, continues to trade roughly 30% below the value of its marketed drugs alone.
The German bank stated that a better-than-anticipated start to any of GSK's upcoming product rollouts could "reinvigorate investor interest" and begin to address 2028+ HIV patent expiry fears.
However, Berenberg expects investors to adopt "a show-me attitude" and noted that while GSK's valuation "remains unchallenging", it prefers Sanofi for pharma value investors.
"GSK trades on 8.7x 2026 adjusted earnings versus non-obesity European peers on 11.5x. On EV/NPV, GSK trades c15% below European non-obesity peers (0.70x versus 0.82x) and c30% below the value of marketed assets alone," said Berenberg, which reiterated its £16.00 target price.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.